Loading...
TrendSpott

TrendSpott

TrendSpott
 
 
Amicus Therapeutics
11.04
-1.43%
 
Recommendation
FOLD Amicus Therapeutics
  Login
 
 
Last Price
 
Change
 
11.04
 
-1.43%
 
 

 
Sentiment
 
  Login to display
 
 

12.64

12.09

11.47

9.26

 
 
1m
3m
6m
1y
 

Summary

  Login to display Amicus Therapeutics (FOLD) recommendation from the last 90 days from financial news and social media.
 

Rewards

Rewards

 Earnings are forecast to grow

Rewards

 Upgraded on attractively valued

 

Risk Analysis

Risk Analysis

 Investors losing their confidence

 
 

Analysts Opinion

Click on the category for more information
 
 
Earnings ×
 

Earnings

3.20
 

TrendSpott

Above analyst estimates

TrendSpott

Reported a weak earnings

 
 
Rating ×
 

Rating

5.00
 

TrendSpott

Upgraded on attractively valued

 
Momentum ×
 

Momentum

NA
 
 
Activity ×
 

Activity

3.78
 

TrendSpott

Investors losing their confidence

 
Future ×
 

Future

5.00
 

TrendSpott

Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is positive and it remained unchanged from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
82%
100%
NA
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is extremely ish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
82%
18%
Positive
Negative
14 out of 17
events present
3 out of 17
events present
 

 
Events Calendar
Click for more information
 
February
S
M
T
W
T
F
S
March
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Strong Earnings
3 Weeks Ago
12.68
-6.35%
 
Strong Earnings
3 Weeks Ago
13.54
+2.65%
 
Investors Activity
3 Weeks Ago
13.18
+1.93%
 
Investors Selling
2 Month Ago
13.05
-1.51%
 
Top Headlines

amicus therapeutics: well positioned to grow faster globally.

Wed Mar 8, 2023

Potential

amicus (fold) q4 earnings miss galafold sales beat estimates. amicus therapeutics fold reported a loss of 19 cents per share in fourth-quarter 2022 wider than the zacks consensus estimate of a loss of 13 cents. the company reported an

Thu Mar 2, 2023

Earnings
Earnings

amicus therapeutics pt raised to $17 at ubs.

Thu Mar 2, 2023

Rating

amicus therapeutics (fold) reports q4 loss tops revenue estimates. amicus therapeutics (fold) came out with a quarterly loss of $0.19 per share versus the zacks consensus estimate of a loss of $0.13. this compares to loss of $0.29 per

Wed Mar 1, 2023

Earnings
Earnings

amicus therapeutics to present at the cowen 43rd annual health care conference. ) today announced that management will participate in a fireside chat at the cowen 43rd annual health care conference in boston ma on monday march 6 2023 at 9:50 a.m. e.t.

Mon Feb 27, 2023

Activity

wellington management group llp cuts stake in amicus therapeutics (fold). fintel reports that wellington management group llp has filed a 13g/a form with the sec disclosing ownership of 8.11mm shares of amicus

Mon Feb 6, 2023

Activity

 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss
 

Receive our daily FOLD alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
TrendSpott

TrendSpott

Get the pulse of the market

 
TrendSpott

TrendSpott

FOLD Amicus Therapeutics

Last Price
11.04
Change
-1.43%
Recommendation
  Login to display
 

Summary

  Login to display Amicus Therapeutics (FOLD) recommendation from the last 90 days from financial news and social media.

 
 
12.64
12.09
11.47
9.26
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Rewards

Rewards

 Earnings are forecast to grow

Rewards

 Upgraded on attractively valued

Risk Analysis

Risk Analysis

 Investors losing their confidence

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
NA
100%
On Track
On Track
On Track
 
82%
18%
Positive
Negative
14 out of 17
events present
3 out of 17
events present
 

Street Opinion

Street view is extremely ish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 
Earnings ×
 

Earnings

3.20
 

TrendSpott

Above analyst estimates

TrendSpott

Reported a weak earnings

 
 
Rating ×
 

Rating

5.00
 

TrendSpott

Upgraded on attractively valued

 
Momentum ×
 

Momentum

NA
 
 
Activity ×
 

Activity

3.78
 

TrendSpott

Investors losing their confidence

 
Future ×
 

Future

5.00
 

TrendSpott

Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is positive and it remained unchanged from the past 3 months

 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Events Calendar
Hover for information
 
February
 
S
M
T
W
T
F
S
 
 
 
March
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Strong Earnings
3 Weeks Ago
12.68
-6.35%
 
Strong Earnings
3 Weeks Ago
13.54
+2.65%
 
Investors Activity
3 Weeks Ago
13.18
+1.93%
 
Investors Selling
2 Month Ago
13.05
-1.51%
 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss

 

Receive our daily FOLD Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines